全文获取类型
收费全文 | 72487篇 |
免费 | 44304篇 |
国内免费 | 8篇 |
专业分类
耳鼻咽喉 | 1487篇 |
儿科学 | 4201篇 |
妇产科学 | 520篇 |
基础医学 | 15362篇 |
口腔科学 | 5085篇 |
临床医学 | 12162篇 |
内科学 | 22754篇 |
皮肤病学 | 7452篇 |
神经病学 | 13187篇 |
特种医学 | 2167篇 |
外科学 | 13664篇 |
综合类 | 11篇 |
一般理论 | 21篇 |
预防医学 | 4092篇 |
眼科学 | 1257篇 |
药学 | 5427篇 |
中国医学 | 1009篇 |
肿瘤学 | 6941篇 |
出版年
2023年 | 21篇 |
2022年 | 42篇 |
2021年 | 1265篇 |
2020年 | 5029篇 |
2019年 | 10799篇 |
2018年 | 10054篇 |
2017年 | 11417篇 |
2016年 | 12057篇 |
2015年 | 11889篇 |
2014年 | 11783篇 |
2013年 | 12234篇 |
2012年 | 3978篇 |
2011年 | 3916篇 |
2010年 | 8847篇 |
2009年 | 5211篇 |
2008年 | 1948篇 |
2007年 | 778篇 |
2006年 | 829篇 |
2005年 | 615篇 |
2004年 | 617篇 |
2003年 | 627篇 |
2002年 | 715篇 |
2001年 | 786篇 |
2000年 | 724篇 |
1999年 | 264篇 |
1998年 | 35篇 |
1997年 | 18篇 |
1996年 | 24篇 |
1995年 | 21篇 |
1994年 | 20篇 |
1993年 | 11篇 |
1992年 | 28篇 |
1991年 | 20篇 |
1990年 | 27篇 |
1989年 | 21篇 |
1988年 | 14篇 |
1987年 | 13篇 |
1986年 | 19篇 |
1985年 | 16篇 |
1984年 | 9篇 |
1982年 | 4篇 |
1981年 | 3篇 |
1979年 | 3篇 |
1978年 | 8篇 |
1976年 | 4篇 |
1974年 | 3篇 |
1973年 | 5篇 |
1969年 | 3篇 |
1967年 | 3篇 |
1966年 | 3篇 |
排序方式: 共有10000条查询结果,搜索用时 698 毫秒
181.
182.
Eduardo Rodrigues‐Pinto Joel Ferreira‐Silva Guilherme Macedo Douglas K. Rex 《Digestive endoscopy》2019,31(5):583-587
Cecal intubation is a critical aspect of effective, complete colonoscopy. Difficult colonoscopy is most often considered as one in which it is challenging or impossible to reach the cecum. It may be a common occurrence due to patient and/or endoscopist factors. Incomplete colonoscopies should be avoided, since patients in this context present an important prevalence of lesions that escape examination. The approach to successful cecal intubation should depend on characterization of the problem as redundant colon or difficult sigmoid colon. Most patients with a prior incomplete colonoscopy can be colonoscoped successfully, if careful attention is paid to technique, using a variety of scopes, colonoscopy methods and additional equipment. Sufficient time should be allotted to make the attempt. 相似文献
183.
Fardin Moradi Vahid Maleki Sevda Saleh‐Ghadimi Fatemeh Kooshki Bahram Pourghassem Gargari 《Clinical and experimental pharmacology & physiology》2019,46(11):975-983
Diabetes, as a low‐grade chronic inflammatory disease, causes disruption in proper function of immune and metabolic system. Chromium is an important element required for normal lipid and glucose metabolism. Chromium deficiency is correlated with elevation in cardiometabolic risk, which results from increased inflammation. This systematic review was conducted to discover the potential roles of chromium on inflammatory biomarkers. Eligible studies were all in vitro, animal and human studies published in English‐language journals from inception until October 2018. PubMed, Scopus, Embase, ProQuest and Google Scholar databases were searched to fined interventional studies from the effects of chromium on inflammatory biomarkers such as tumour necrosis factor a (TNF‐a), C‐reactive protein (CRP), interleukins, monocyte chemoattractant protein–1 (MCP‐1), intercellular adhesion molecule‐1 (ICAM‐1) and adipocytokines in hyperglycaemia and diabetes. Out of 647 articles found in the search, only 14 articles were eligible for analysis, three in vitro studies, eight animal studies and three human studies. Twelve of the 14 studies included in this review, chromium significantly decreased inflammatory factors. The findings of this review indicate, based on in vitro and in vivo studies, that chromium might have potential anti‐inflammatory properties, but some of the studies did not show anti‐inflammatory effects for chromium (two studies). There are only three studies in humans with controversial results. Therefore, more consistent randomized double‐blind controlled trials are needed to reach relevant clinical recommendations, as well as to determine the precise mechanism, of chromium on inflammation in diabetes. 相似文献
184.
Yoshiki Imamura Takahiro Shinozaki Akiko Okada‐Ogawa Noboru Noma Masahiro Shinoda Koichi Iwata Akihiko Wada Osamu Abe Kelun Wang Peter Svensson 《Journal of oral rehabilitation》2019,46(6):574-587
Burning mouth syndrome (BMS) is a chronic oro‐facial pain disorder of unknown cause. It is more common in peri‐ and post‐menopausal women, and sex hormone dysregulation is believed to be an important causative factor. Psychosocial events often trigger or exacerbate symptoms, and persons with BMS appear to be predisposed towards anxiety and depression. Atrophy of small nerve fibres in the tongue epithelium has been reported, and potential neuropathic mechanisms for BMS are now widely investigated. Historically, BMS was thought to comprise endocrinological, psychosocial and neuropathic components. Neuroprotective steroids and glial cell line–derived neurotrophic factor family ligands may have pivotal roles in the peripheral mechanisms associated with atrophy of small nerve fibres. Denervation of chorda tympani nerve fibres that innervate fungiform buds leads to alternative trigeminal innervation, which results in dysgeusia and burning pain when eating hot foods. With regard to the central mechanism of BMS, depletion of neuroprotective steroids alters the brain network–related mood and pain modulation. Peripheral mechanistic studies support the use of topical clonazepam and capsaicin for the management of BMS, and some evidence supports the use of cognitive behavioural therapy. Hormone replacement therapy may address the causes of BMS, although adverse effects prevent its use as a first‐line treatment. Selective serotonin reuptake inhibitors (SSRIs) and serotonin and noradrenaline reuptake inhibitors (SNRIs) may have important benefits, and well‐designed controlled studies are expected. Other treatment options to be investigated include brain stimulation and TSPO (translocator protein 18 kDa) ligands. 相似文献
185.
A. Caldern‐Larraaga D. L. Vetrano L. Ferrucci S. W. Mercer A. Marengoni G. Onder M. Eriksdotter L. Fratiglioni 《Journal of internal medicine》2019,285(3):255-271
This review discusses the interplay between multimorbidity (i.e. co‐occurrence of more than one chronic health condition in an individual) and functional impairment (i.e. limitations in mobility, strength or cognition that may eventually hamper a person's ability to perform everyday tasks). On the one hand, diseases belonging to common patterns of multimorbidity may interact, curtailing compensatory mechanisms and resulting in physical and cognitive decline. On the other hand, physical and cognitive impairment impact the severity and burden of multimorbidity, contributing to the establishment of a vicious circle. The circle may be further exacerbated by people's reduced ability to cope with treatment and care burden and physicians’ fragmented view of health problems, which cause suboptimal use of health services and reduced quality of life and survival. Thus, the synergistic effects of medical diagnoses and functional status in adults, particularly older adults, emerge as central to assessing their health and care needs. Furthermore, common pathways seem to underlie multimorbidity, functional impairment and their interplay. For example, older age, obesity, involuntary weight loss and sedentarism can accelerate damage accumulation in organs and physiological systems by fostering inflammatory status. Inappropriate use or overuse of specific medications and drug–drug and drug–disease interactions also contribute to the bidirectional association between multimorbidity and functional impairment. Additionally, psychosocial factors such as low socioeconomic status and the direct or indirect effects of negative life events, weak social networks and an external locus of control may underlie the complex interactions between multimorbidity, functional decline and negative outcomes. Identifying modifiable risk factors and pathways common to multimorbidity and functional impairment could aid in the design of interventions to delay, prevent or alleviate age‐related health deterioration; this review provides an overview of knowledge gaps and future directions. 相似文献
186.
187.
Three‐Dimensional Echocardiographic Evaluation of Mitral Apparatus during Preload Manipulation in Patients with Hypertrophic Cardiomyopathy
下载免费PDF全文
![点击此处可从《Echocardiography (Mount Kisco, N.Y.)》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Hyemoon Chung M.D. Ji Hyun Yoon M.D. Young Won Yoon M.D. Ph.D. Ji Young Chung B.N. Jung‐Joon Cha M.D. Jong‐Youn Kim M.D. Ph.D. Pil‐Ki Min M.D. Ph.D. Byoung‐Kwon Lee M.D. Ph.D. Bum‐Kee Hong M.D. Ph.D. Se‐Joong Rim M.D. Ph.D. Hyuck Moon Kwon M.D. Eui‐Young Choi M.D. Ph.D. 《Echocardiography (Mount Kisco, N.Y.)》2015,32(8):1261-1269
188.
Stanislas Grassin‐Delyle Michaela Semeraro Frantz Foissac Naim Bouazza Haleema Shakur‐Still Ian Roberts Jean‐Marc Treluyer Saïk Urien 《Fundamental & clinical pharmacology》2019,33(6):670-678
Tranexamic acid (TXA) is an antifibrinolytic drug that reduces surgical blood loss and death due to bleeding after trauma and post‐partum haemorrhage. One key issue for treatment success is early administration. While usually given intravenously, oral and intramuscular use would be useful in specific circumstances. Therefore, an understanding of TXA pharmacokinetics when given via different routes is valuable. The aim of this study was to perform an individual participant data meta‐analysis of pharmacokinetic studies with TXA given to healthy volunteers via different routes. We searched the following databases: PubMed, Web of Science, Wiley Online Library, Elsevier Science Direct and J‐STAGE. Individual subject data were extracted when available, otherwise arithmetic means were used. A population pharmacokinetic model was developed using nonlinear mixed effect modelling. Seven studies were included in the analysis with data from 10 patients for the IV route, six patients for the IM route and 114 patients for the oral route. The pharmacokinetics was ascribed to a two‐compartment model, and the main covariate was allometrically scaled bodyweight. Oral and IM bioavailabilities were 46 and 105%, respectively. For a 70 kg bodyweight, the population estimates were 7.6 L/h for clearance, 17.9 L for the volume of the central compartment, 2.5 L/h for the diffusional clearance and 16.6 L for the peripheral volume of distribution. Larger well‐designed studies are needed to describe the pharmacokinetics of TXA when given IM or as an oral solution before these can be recommended as alternatives to IV. 相似文献
189.
Which infants with eczema are at risk of food allergy? Results from a population‐based cohort
下载免费PDF全文
![点击此处可从《Clinical and experimental allergy》网站下载免费的PDF全文](/ch/ext_images/free.gif)